SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Type 1 Diabetes
Pipeline
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
3/25/2026
Quarterly Report 2 25/26
3/23/2026
NOTICE OF EXTRAORDINARY GENERAL MEETING IN DIAMYD MEDICAL AKTIEBOLAG
3/23/2026
Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial
3/19/2026
Diamyd Medical receives Notice of Grant in Japan for insulin-based antigen therapy patent in type 1 diabetes
3/2/2026
American Diabetes Association 86th Scientific Sessions to feature retogatein Phase 3 trial in dedicated symposium
2/24/2026
Diamyd Medical announces finalization of database for interim analysis in Phase 3 DIAGNODE-3 trial
2/9/2026
Diamyd Medical receives Notice of Allowance for key retogatein US patent
1/28/2026
Quarterly Report 1 25/26
1/23/2026
Diamyd Medical deepens long-term manufacturing collaboration for retogatein
1/12/2026
Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research